What is the revenue and EPS growth rate for Sanara year over year?

What is the market's earnings forecast for Sanara next quarter?

What is Sanara's latest dividend and current dividend yield?

Did Sanara beat or miss consensus estimates last quarter?

What were the key takeaways from Sanara's earnings call?

What does Sanara do and what are its main business segments?

What factors drove the changes in Sanara's revenue and profit?

What guidance did Sanara's management provide for the next earnings period?

- **Strategic Shift**: Discontinued THP to focus on Surgical business, freeing $5.5-$6.5 million in 2025 for core growth.
- **Revenue Surge**: Q3 Surgical revenue $26.3 million (+22% YoY), trailing 12-month $102 million (+31% YoY), driven by soft tissue repair products.
- **Operational Efficiency**: 31% revenue growth with 157% EBITDA increase, enabled by flat headcount and distributor network expansion.
- **Future Growth**: Q4 2025 revenue expected +10-15% YoY (excluding one-time 2024 impact), with Surgical business targeting 10-20% annual growth.
- **Clinical Validation**: Published studies confirm CellerateRX efficacy in complex cases, supporting surgeon adoption.


**【CEO Summary Section】**
- **THP Discontinuation**: Announced cessation of Tissue Health Plus (THP) operations, with total cash investment in 2025 expected to be $5.5-$6.5 million. THP will be classified as discontinued operations, freeing resources for Surgical business.
- **Revenue Growth**: Q3 2025 Surgical net revenue $26.3 million (+22% YoY), driven by 24% increase in soft tissue repair products (CellerateRX, BIASURGE). Full-year trailing 12-month revenue $102 million (+31% YoY).
- **Commercial Strategy**: Expanded distributor network to 400+ (from 300+), sold into 1,200+ healthcare facilities (vs. 1,000+ prior year), and increased surgeon penetration in existing facilities. Focus on new specialties beyond spine/orthopedics.
- **Operational Highlights**: Published clinical evidence in high-impact journals demonstrating CellerateRX efficacy in complex cases. OsStic (periarticular fracture product) on track for U.S. launch Q1 2027, with BMI completing all regulatory milestones.

**【CFO Financial Commentary】**
- **Gross Profit**: Q3 2025 gross profit $24.5 million (+24% YoY), margin 93% of net revenue (vs. 91% prior year).
- **Operating Expenses**: SG&A $21.5 million (+14% YoY), driven by salesforce expansion and marketing. R&D $0.2 million (+31% YoY).
- **Net Income**: Net income from continuing ops $0.8 million ($0.09 EPS), vs. $0.2 million loss prior year. Adjusted EBITDA $4.9 million (+2.3 million YoY).
- **Cash Flow**: Q3 operating cash flow $2.2 million. Total cash $14.9 million, debt $45.1 million.

**【Q&A Key Highlights】**
- **Penetration Strategy**: Focus on educating surgeons on clinical/economic benefits of products. Distributor network and direct salesforce driving new facility adoption.
- **Operating Leverage**: Flat headcount (40 W-2 reps, 400 distributors) enabling 31% revenue growth with EBITDA up 157% YoY. Expect continued leverage as THP costs decline.
- **Growth Outlook**: Q4 2025 revenue expected to grow high single to low teens YoY (excluding $1.8 million one-time 2024 hurricane impact). Long-term Surgical business seen as 10-20% grower with improving margins.
- **THP Lessons**: Strategic review process confirmed limited partner interest, aligning with Board decision to focus on core Surgical business.


SMTI

SMTI fundamentals

You can ask Aime